📰 BloombergBloombergCodex · 实盘不做把握 5/10
北京时间·🕒 发布 13:01:32时区推断·⟳ 抓取 13:17:11·⚡ 决策 07-23 13:22:31 +5m20s·96.5 天前
达索系统拟最高20亿美元收购ArisGlobal扩展生命科学软件
达索系统拟以18亿美元现金加最高2亿美元或有付款收购ArisGlobal，补强药物开发、监管和安全监测软件。
📄 原文Bloomberg↗ 原文
Dassault Systèmes SE will buy drug trial software maker ArisGlobal for as much as $2 billion as the French firm expands…
不做 达索系统（DSY.FR）
收购方支付最高20亿美元，战略补强与整合/现金支出并存，短线方向不够清晰。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-23 · 扩散 medium · price-in 风险 medium ↗
关键理由
- 达索系统拟以18亿美元现金加最高2亿美元或有付款收购ArisGlobal，补强药物开发、监管和安全监测软件。
主要风险
- 交易金额最高20亿美元，而公司生命科学业务此前承压；收购能否改善增长需中期验证，短线未必增厚。
工具调用 · 历史记录,结果未知(2 种)
- stock_quote · 结果未知
- search_processed_events · 结果未知
原文全文
展开原文 · 1,939 字
Dassault Systèmes SE will buy drug trial software maker ArisGlobal for as much as $2 billion as the French firm expands its push into life sciences.
Dassault will buy the firm from Nordic Capital, a Swedish private equity group, the French company said in a statement on Thursday. The payment includes $1.8 billion in cash and an additional $200 million in payouts, the company said.
The deal is the company’s first major acquisition since it pushed out its chairman in February in a surprise move following a steep decline in its share price. Dassault, which is controlled by a family that’s at the heart of France’s defense industry, has struggled this year due to fears that artificial intelligence will disrupt software businesses.
Read More: Dassault Chair’s Abrupt Exit Follows Sharp Drop in Share Price
The group reported a revenue of €1.56 billion in the second quarter, up 2% from the previous year. That compares to an average analyst estimate of €1.54 billion according to data compiled by Bloomberg. Dassault shares have lost about 26% so far this year.
Dassault specializes in creating “virtual twins” of complex machines, a field threatened by emerging AI “world models” that help systems navigate the physical world. Earlier this year, the firm has been among the companies spanning multiple industries getting swept up in a global selloff of stocks seen as vulnerable to disruption by AI tools.
The company’s life sciences arm has been a drag on its overall performance, with revenue in the division falling 12% in the first quarter compared to a year earlier. Chief Executive Officer Pascal Daloz said in an earnings call in February that Dassault remains committed to life sciences as AI redefines the sector.
Nordic bought a majority stake in the US-based ArisGlobal in 2019 and later expanded its holding. ArisGlobal uses AI to help life science companies with drug development, regulation and safety monitoring.
Dassault will buy the firm from Nordic Capital, a Swedish private equity group, the French company said in a statement on Thursday. The payment includes $1.8 billion in cash and an additional $200 million in payouts, the company said.
The deal is the company’s first major acquisition since it pushed out its chairman in February in a surprise move following a steep decline in its share price. Dassault, which is controlled by a family that’s at the heart of France’s defense industry, has struggled this year due to fears that artificial intelligence will disrupt software businesses.
Read More: Dassault Chair’s Abrupt Exit Follows Sharp Drop in Share Price
The group reported a revenue of €1.56 billion in the second quarter, up 2% from the previous year. That compares to an average analyst estimate of €1.54 billion according to data compiled by Bloomberg. Dassault shares have lost about 26% so far this year.
Dassault specializes in creating “virtual twins” of complex machines, a field threatened by emerging AI “world models” that help systems navigate the physical world. Earlier this year, the firm has been among the companies spanning multiple industries getting swept up in a global selloff of stocks seen as vulnerable to disruption by AI tools.
The company’s life sciences arm has been a drag on its overall performance, with revenue in the division falling 12% in the first quarter compared to a year earlier. Chief Executive Officer Pascal Daloz said in an earnings call in February that Dassault remains committed to life sciences as AI redefines the sector.
Nordic bought a majority stake in the US-based ArisGlobal in 2019 and later expanded its holding. ArisGlobal uses AI to help life science companies with drug development, regulation and safety monitoring.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。